PTH1R

Septerna Presents Preclinical Data at ENDO 2024 Highlighting Therapeutic Potential of its GPCR Drug Discovery Platform

Retrieved on: 
月曜日, 6月 3, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ENDO, Molecule, Injection (medicine), Thyroid, Endocrine system, Patient, Hyperthyroidism, TED, Concept, Peptide, Autoantibody, Kidney, Hypoparathyroidism, PTH1R, Graves' ophthalmopathy, Gene, PTH, Tissue, G protein-coupled receptor, Poster, Drug discovery

The data were presented in two poster presentations and a rapid-fire oral presentation during the Endocrine Society’s Annual Meeting (ENDO 2024) held June 1-4, 2024, in Boston, MA.

Key Points: 
  • The data were presented in two poster presentations and a rapid-fire oral presentation during the Endocrine Society’s Annual Meeting (ENDO 2024) held June 1-4, 2024, in Boston, MA.
  • These results suggest that oral small molecule PTH1R agonists may be suitable alternatives to injectable PTH peptides for the treatment of hypoparathyroidism.
  • The company plans to initiate a Phase 1 trial with its lead PTH1R agonist candidate in healthy volunteers in late 2024.
  • The data also demonstrated sustained control of serum calcium and phosphate levels over 28 days with daily oral administration.

Septerna to Present Preclinical Data from GPCR Drug Discovery Engine at ENDO 2024

Retrieved on: 
月曜日, 5月 20, 2024
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ENDO, Molecule, Patient, PTH1R, G protein-coupled receptor, TSHR, GPCR, Endocrine system, Hypoparathyroidism, Concept, Injection (medicine), Phosphate, Pharmaceutical industry

Septerna, a biotechnology company discovering and advancing novel, oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that the company will present the first preclinical data on the company’s parathyroid hormone 1 receptor (PTH1R) and thyroid stimulating hormone receptor (TSHR) programs at the Endocrine Society’s Annual Meeting (ENDO 2024) held June 1-4 in Boston.

Key Points: 
  • Septerna, a biotechnology company discovering and advancing novel, oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that the company will present the first preclinical data on the company’s parathyroid hormone 1 receptor (PTH1R) and thyroid stimulating hormone receptor (TSHR) programs at the Endocrine Society’s Annual Meeting (ENDO 2024) held June 1-4 in Boston.
  • “We are excited to present for the first time new preclinical findings from our breakthrough GPCR Native Complex Platform™ at ENDO 2024, marking a significant moment in our evolution to a clinical-stage company,” said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna.
  • “Led by our PTH1R program, which has the potential to be the first oral replacement therapy for hypoparathyroidism, these promising preclinical data validate our approach to discover novel GPCR-targeted medicines and reaffirm our dedication to deliver transformative therapies to patients in need of better treatment options.”
    Title: Characterization of a Novel Oral Small Molecule PTH1R Agonist: Proof of Concept for an Alternative to Injectable Peptide-based Therapy for Hypoparathyroidism
    Poster Session (P085): Bone and Mineral Metabolism: Clinical Osteoporosis
    Oral Abstract and Rapid-Fire Session (OR14): Bone and Mineral Metabolism: PTH, Calcium, and Phosphate Metabolism
    Presenter: Jun Zhang, Ph.D., Senior Director of Disease Biology, Septerna
    Presenter: Amer Mirza, Ph.D., Vice President, Disease Biology and Translational Sciences, Septerna

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
水曜日, 2月 28, 2024
ENDO, SAN, Congenital adrenal hyperplasia, Holocene, Carcinoid syndrome, Research, Entrepreneurship, Investment, FDA, Food, Webcast, Growth, Graves' ophthalmopathy, Primary hyperparathyroidism, PTH1R, Somatostatin, Conference, Endocrinology, Safety, TSH, Patient, CAH, Trial of the century, NDA, PHPT, Pharmaceutical industry

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • ET Today
    SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • We also expect full results from our Phase 2 study in carcinoid syndrome in the first half of this year.
  • In December 2023, Crinetics reported an initial analysis of data from a subset of 27 patients.
  • Earlier today, February 28, 2024, Crinetics announced a private placement equity financing for gross proceeds of approximately $350 million.

Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors

Retrieved on: 
火曜日, 2月 6, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, McKinsey & Company, Shalini, Bristol Myers Squibb, Lactococcus lactis, Harvard University, Organon, Agenus, Patient, GPCR, Drug discovery, MBA, Endocrinology, Neurocrine Biosciences, Therapy, Assistant, Drug development, Hypoparathyroidism, Acquisition, Goldman Sachs, G protein-coupled receptor, Metabolism, University, Mirati Therapeutics, PTH1R, Precigen, Pharmacy, Internal medicine, Pharmaceutical industry

Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.

Key Points: 
  • Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.
  • Shalini brings a wealth of strategic, financial, and operational experience, having led or advised several successful private and public biotech companies.
  • Bernard Coulie brings more than two decades of senior leadership experience and drug development expertise to the Septerna board.
  • Shalini Sharp has been in the life sciences industry for over 25 years, having spent 14 years as a Chief Financial Officer.

Septerna Bolsters Leadership Team as the Company Advances its Multi-Product Pipeline Toward Clinical Studies

Retrieved on: 
木曜日, 8月 31, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, University, Puma Biotechnology, Amgen, Gilead Sciences, Human resources, Therapy, Communes of Burundi, G protein-coupled receptor, Culture, Nephrology, Hypoparathyroidism, University of East London, Multiple sclerosis, PTH1R, Drug discovery, Certification, Growth, Breast cancer, IND, First Peoples' Cultural Council, Cholangiocarcinoma, TSHR, Management, Pharmaceutical industry, Laila Al Shaikhli, GPCR, Pharmacology

Dave brings extensive experience in preclinical and clinical development across therapeutic areas, including endocrine disorders, where two of our lead programs are focused.

Key Points: 
  • Dave brings extensive experience in preclinical and clinical development across therapeutic areas, including endocrine disorders, where two of our lead programs are focused.
  • I look forward to advancing these groundbreaking therapeutics toward the clinic and ultimately to patients.”
    “This is an exciting time at Septerna.
  • The company is poised for significant growth as it accelerates the development of multiple pipeline products.
  • As Global Head of Human Resources, Corporate Functions, Shaikhly sat on the human resources leadership team and worked with the CEO’s direct reports on their global organization’s people agenda.

Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
火曜日, 8月 8, 2023
ENDO, TSH, Maintenance, KOL, Endocrinology, Carcinoid syndrome, Sequoyah, Glomus tumor, NDA, Congenital adrenal hyperplasia, Holocene, History, Octreotide, Graves' ophthalmopathy, Acromegaly, Entrepreneurship, Investment, PTH1R, SAN, PHPT, Primary hyperparathyroidism, Hospital, Research, FDA, Conference, Massachusetts General Hospital, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Congenital hyperinsulinism, Pharmaceutical industry, Cryptocurrency

SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the second quarter ended June 30, 2023.
  • Enrollment in our Phase 3 PATHFNDR-2 study is also now complete and we anticipate topline results in the first quarter of 2024,” said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics.
  • “Unfortunately, we also suffered a setback with our CRN04777 program and made the difficult decision to wind down its development.
  • PATHFNDR-1 is a placebo-controlled Phase 3 clinical study of oral paltusotine in participants with acromegaly switching from standard-of-care peptide depots.

Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines

Retrieved on: 
火曜日, 7月 11, 2023
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional Services, Clinical Trials, Seizure, Kidney failure, Drug development, Therapy, Venture round, G protein-coupled receptor, Goldman Sachs, Arrhythmia, Hypoparathyroidism, Lead, Brain, PTH, Fatigue, Muscle weakness, Richard Driehaus, Protein, GPCR, Third Rock Ventures, Patient, Mirae Asset Financial Group, PTH1R, Parathyroid hormone, TSHR, Pharmaceutical industry

Septerna , a biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced the closing of a $150 million Series B financing.

Key Points: 
  • Septerna , a biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced the closing of a $150 million Series B financing.
  • In conjunction with the financing, Jake Simson, Ph.D., partner at RA Capital Management, will join Septerna’s board of directors.
  • This is an exciting time for GPCR drug development, and we are eager to move our novel products toward clinical development.
  • Septerna is focused on developing a first-in-class, oral small molecule PTH1R agonist designed to treat all patients with hypoparathyroidism.

New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023

Retrieved on: 
水曜日, 6月 21, 2023
ENDO, Rat, FISU World University Games, Pain, Graves' ophthalmopathy, A1C, Patient, Hypercalcaemia, Primary hyperparathyroidism, SST2, Health, Hyperthyroidism, Memory, PTH1R, Fatigue, Thyroid, Camp, PRO, Weakness, HHM, Acromegaly, Headache, Safety, Growth hormone, Cancer, Medicine, Biomarker, History, Calcium, ASD, Swelling, Autoimmune disease, Endocrine Society, Perspiration, Medical school, Human, Blood pressure, Exophthalmos, TSH, Malignancy, Osteoporosis, Endocrine system, Arthralgia, Sequoyah, Saint Andrew's Society, PHPT, Poster, TSHR, TED, Pharmaceutical industry, Entrepreneurship, Endocrinology

SAN DIEGO, June 21, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) presented efficacy, safety and patient-reported outcome (PRO) data at ENDO 2023 for paltusotine, an experimental, once-daily, oral, small molecule somatostatin receptor type 2 (SST2) agonist in Phase 3 clinical development for the treatment of acromegaly. The Endocrine Society’s annual meeting, ENDO 2023, was held June 15-18, 2023, in Chicago, Illinois.

Key Points: 
  • The Endocrine Society’s annual meeting, ENDO 2023 , was held June 15-18, 2023, in Chicago, Illinois.
  • The ASD score was a composite representing participants’ daily impressions of common acromegaly symptoms including headache, joint pain, sweating, fatigue, weakness, swelling, and numbness/tingling.
  • Approximately 90% of participants said they preferred once-daily, oral paltusotine over current standard of care of injected SRLs when asked after one year of treatment.
  • The data presented in a poster at ENDO on June 17th show Crinetics’ PTH1R antagonist suppressing PTH-stimulated increases in ionized calcium, urinary cAMP, and bone resorption biomarkers in rats.

Crinetics to Highlight Broad Pipeline at ENDO 2023

Retrieved on: 
金曜日, 6月 9, 2023
ENDO, Entrepreneurship, Maintenance, Endocrinology, Endocrine system, TSHR, Peptide hormone, FISU World University Games, Policy, Foot, Hyperparathyroidism, Saint Andrew's Society, Acromegaly, PTH1R, Physician, Pharmacokinetics, SAN, Endocrine Society, Primary hyperparathyroidism, Neuroendocrinology, Drug discovery, Medical school, Liver, SST2, Graves' ophthalmopathy, Hyperthyroidism, Memory, Pharmaceutical industry, Vaccine, Medical imaging, Safety

SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the Endocrine Society’s annual meeting, which is being held June 15-18, 2023 in Chicago, Illinois.

Key Points: 
  • SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the Endocrine Society’s annual meeting, which is being held June 15-18, 2023 in Chicago, Illinois.
  • An upcoming oral presentation will review previously reported two-year data from the company’s ACROBAT Advance open-label extension study of paltusotine in acromegaly.
  • I would like to thank the Endocrine Society for awarding this prize, which is a testament to all of the groundbreaking work being done by the Crinetics team.”
    The posters and oral presentations will be made available on the Crinetics website in accordance with the ENDO embargo policy.
  • For attendees of ENDO 2023, Crinetics staff will be available to address questions and discuss pipeline programs at the company booth (#1623).